Provided by Tiger Trade Technology Pte. Ltd.

Alaunos Therapeutics

1.98
+0.937689.30%
Volume:80.55M
Turnover:156.66M
Market Cap:5.78M
PE:-1.12
High:2.09
Open:1.74
Low:1.62
Close:1.05
52wk High:4.50
52wk Low:0.7190
Shares:2.92M
Float Shares:1.89M
Volume Ratio:3,927.29
T/O Rate:4258.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7684
EPS(LYR):-2.1977
ROE:-185.95%
ROA:-81.13%
PB:8.87
PE(LYR):-0.90

Loading ...

Alaunos Therapeutics - Buys Velaris Therapeutics on October 13, 2026 - SEC Filing

THOMSON REUTERS
·
11 mins ago

Alaunos Therapeutics: Prices $350 Mln Pipe Offering of 687,789 Common Shares at $1.44 and 243,063 Series C Preferred at $1,435.70 - SEC Filing

THOMSON REUTERS
·
11 mins ago

Alaunos Therapeutics Completes Acquisition of Velaris Therapeutics

Reuters
·
2 hours ago

Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

THOMSON REUTERS
·
2 hours ago

Alaunos Therapeutics Faces Nasdaq Delisting, Seeks Hearing

TIPRANKS
·
Oct 10

Alaunos Faces NASDAQ Delisting Threat over Failure to Meet $2.5 Million Stockholders’ Equity Rule

Reuters
·
Oct 10

Alaunos Therapeutics Announces New Registered Direct Offering

TIPRANKS
·
Sep 23

Alaunos Therapeutics Prices Registered Direct Offering at USD 1.46 Per Share for USD 1.12 Million Gross Proceeds

Reuters
·
Sep 18

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Sep 18

Alaunos Therapeutics Cuts Stockholder Meeting Quorum Requirement to One-Third from Majority

Reuters
·
Sep 17

Alaunos Net Loss Narrows to $1.9 Million in Q2 2026; Revenue Posts no Revenue in H1 2026

Reuters
·
Aug 15

Alaunos Reports New Preclinical Analysis Showing Aln1003 Lowers Liver Weight in 48-day DIO Mouse Study

Reuters
·
Jun 29

Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies

TIPRANKS
·
May 27

Alaunos publishes investor presentation on ALN1003 preclinical data

Reuters
·
May 26

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

TIPRANKS
·
May 18

Alaunos reports preclinical ALN1003 data in obesity mouse studies showing improved insulin markers

Reuters
·
May 18

Alaunos Therapeutics Inc - Aln1003-Treated Animals Had Significantly Lower Homa-Ir Scores After Body Fat Adjustment

THOMSON REUTERS
·
May 18

Alaunos Reports Preclinical Aln1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

THOMSON REUTERS
·
May 18

Alaunos Therapeutics Inc - Cash Runway Extends Into Q2 2026

THOMSON REUTERS
·
May 18

Alaunos net loss widens to $1 million in Q1 FY26

Reuters
·
May 16